secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001213900-25-111310
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M
------------------------------------------------------------------------

- Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.
- Full $100M repayment from Scilex completed; $27M received in the period.
- Total assets up 42% to $220.5M; driven by cash returns and unrealized gains on Alpha Tau (DRTS).
- R&D expenses fell to $4.4M from $4.9M; G&A rose to $5.0M from $4.3M.
- Unrealized fair-value gains on equity holdings in Alpha Tau and other investments contributed to income.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/0001213900-25-111310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025111310/ea0265949-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-111310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer